Trial reportThorax2022
Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial.
Trial report in Thorax, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Evolution of body image across treatment eras: a systematic review in young people and adults living with cystic fibrosis.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Impact of Digital Interventions on the Treatment Burden of Patients With Chronic Conditions: Systematic Review.Journal of medical Internet research · 2025Pooled it
- Medication adherence to CFTR modulators in patients with cystic fibrosis: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2024Pooled it
- Nebuliser systems for drug delivery in cystic fibrosis.The Cochrane database of systematic reviews · 2023Pooled it
- Interventions for improving adherence to airway clearance treatment and exercise in people with cystic fibrosis.The Cochrane database of systematic reviews · 2023Pooled it
- Digital technology for early identification of exacerbations in people with cystic fibrosis.The Cochrane database of systematic reviews · 2023Pooled it
- Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis.The Cochrane database of systematic reviews · 2023Pooled it
- A RCT to explore the effectiveness of supporting adherence to nebuliser medication in adults with cystic fibrosis: fidelity assessment of study interventions.BMC pulmonary medicine · 2024Trial
- CF Tummy Tracker: A Cystic Fibrosis-Specific Patient-Reported Outcome Measure for Daily Gastrointestinal Symptom Burden.Mayo Clinic proceedings. Digital health · 2025Article
- Changing practice in cystic fibrosis: Implementing objective medication adherence data at every consultation, a learning health system and quality improvement collaborative.Learning health systems · 2025Article
- Health State Utilities Associated With Treatment Burden in Cystic Fibrosis: A Patient Valuation Study.CHEST pulmonary · 2025Article
- Leveraging Habits to Improve Adherence to Gout Medications: A Qualitative Study.ACR open rheumatology · 2024Article
- Experiences Among Patients With Cystic Fibrosis in the MucoExocet Study of Using Connected Devices for the Management of Pulmonary Exacerbations: Grounded Theory Qualitative Research.JMIR formative research · 2024Article
- Diagnosis and Management of Cystic Fibrosis Exacerbations.Seminars in respiratory and critical care medicine · 2023Review
- Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis.The Cochrane database of systematic reviews · 2023Review
- A year in review (2022): Modulators and COVID19, the story goes on….Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2023Review
- A model-based economic analysis of the CFHealthHub intervention to support adherence to inhaled medications for people with cystic fibrosis in the UK.International journal of technology assessment in health care · 2023Article
- The CFHealthHub Learning Health System: Using Real-Time Adherence Data to Support a Community of Practice to Deliver Continuous Improvement in an Archetypal Long-Term Condition.Healthcare (Basel, Switzerland) · 2022Review
- Article
- A year in review: Real world evidence, functional monitoring and emerging therapeutics in 2021.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2022Review
Corrections and comments
- Commented on by
Authors and funding
18 authors.
Funding
Abstract
introductionRecurrent pulmonary exacerbations lead to progressive lung damage in cystic fibrosis (CF). Inhaled medications (mucoactive agents and antibiotics) help prevent exacerbations, but objectively measured adherence is low. We investigated whether a multi-component (complex) self-management intervention to support adherence would reduce exacerbation rates over 12 months.
methodsBetween October 2017 and May 2018, adults with CF (aged ≥16 years; 19 UK centres) were randomised to the intervention (data-logging nebulisers, a digital platform and behavioural change sessions with trained clinical interventionists) or usual care (data-logging nebulisers). Outcomes included pulmonary exacerbations (primary outcome), objectively measured adherence, body mass index (BMI), lung function (FEV
resultsAmong intervention (n=304) and usual care (n=303) participants (51% female, median age 31 years), 88% completed 12-month follow-up. Mean exacerbation rate was 1.63/year with intervention and 1.77/year with usual care (adjusted ratio 0.96; 95% CI 0.83 to 1.12; p=0.64). Adjusted mean differences (95% CI) were in favour of the intervention versus usual care for objectively measured adherence (9.5% (8.6% to 10.4%)) and BMI (0.3 (0.1 to 0.6) kg/m
conclusionsWhile pulmonary exacerbations and FEV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.